| Chimerix: Potential 'First' In Targeting Recurrent High-Grade Glioma Patients |
The company holds potential to have first approval of dordaviprone for the treatment of recurrent H3 K27M mutant high-grade glioma patients; PDUFA with Priority Review date of August 18th of 2025. The global brain tumor therapeutics market is expected to grow to $5.28 billion by 2030; the Company notes that it could obtain >$1 billion in revenues in the United States alone. Phase 3 ACTION study using dordaviprone for the treatment of front-line H3 K27M mutant high-grade glioma patients to have OS interim data readout in Q3 of 2025. |
seekingalpha.com |
2025-02-20 19:25:01 |
Czytaj oryginał (ang.) |
| Here's Why Momentum in Chimerix (CMRX) Should Keep going |
Chimerix (CMRX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move. |
zacks.com |
2025-02-20 11:50:27 |
Czytaj oryginał (ang.) |
| Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
DURHAM, N.C., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on February 12, 2025, the Compensation Committee of Chimerix's Board of Directors granted inducement awards to three new employees of non-statutory stock options to purchase up to a total of 270,000 shares of Chimerix's common stock. The Compensation Committee of Chimerix's Board of Directors approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing rule 5635(c)(4). |
globenewswire.com |
2025-02-18 18:01:00 |
Czytaj oryginał (ang.) |
| CMRX Stock Skyrockets in 3 Months: Here's What You Should Know |
Chimerix stock surges 324% in three months following NDA submission for high-grade glioma drug, dordaviprone, for accelerated approval in the United States. |
zacks.com |
2025-01-31 13:47:18 |
Czytaj oryginał (ang.) |
| Chimerix to Present at JonesTrading Virtual Precision Medicine Symposium |
DURHAM, N.C., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Andriole, Chief Executive Officer, and Tom Riga, Chief Operating and Commercial Officer, will participate in a fireside chat at the JonesTrading Virtual Precision Medicine Symposium on Monday, February 3, 2025 at 11:00 a.m. ET. |
globenewswire.com |
2025-01-29 18:15:00 |
Czytaj oryginał (ang.) |
| Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
DURHAM, N.C., Jan. 24, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on January 17, 2025, the Compensation Committee of Chimerix's Board of Directors granted inducement awards to six new employees of non-statutory stock options to purchase up to a total of 355,000 shares of Chimerix's common stock. The Compensation Committee of Chimerix's Board of Directors approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing rule 5635(c)(4). |
globenewswire.com |
2025-01-24 18:01:00 |
Czytaj oryginał (ang.) |
| Chimerix Submits Dordaviprone New Drug Application for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma |
Secures Access of Up To $30 Million to Support Potential Launch Through Silicon Valley Bank Credit Facility Secures Access of Up To $30 Million to Support Potential Launch Through Silicon Valley Bank Credit Facility |
globenewswire.com |
2024-12-30 09:00:00 |
Czytaj oryginał (ang.) |
| Chimerix: Big News, Big Moves, So Maybe Now's The Time To Buy |
Chimerix, Inc.'s dordaviprone shows promise in treating H3 K27M-positive glioma, with a potential FDA approval and commercial launch by Q3 2025. CMRX's strong clinical data and high unmet need in diffuse midline glioma bolster confidence in FDA approval, despite potential timeline uncertainties. Financially, CMRX has a cash runway of 6–7 quarters, sufficient to reach an FDA decision, but risks of dilution remain. |
seekingalpha.com |
2024-12-11 16:19:24 |
Czytaj oryginał (ang.) |
| Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End |
Potential Approval in Q3 2025 in Recurrent H3 K27M-Mutant Diffuse Glioma Submission Plan Follows Productive and Collaborative Pre-NDA Interactions with FDA Company to Host Conference Call on Tuesday, December 10 at 8:30 AM ET DURHAM, N.C., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that, following extensive dialogue with the U.S. Food and Drug Administration (FDA), the Company plans to submit a complete New Drug Application (NDA) seeking accelerated approval for dordaviprone as a treatment for recurrent H3 K27M-mutant diffuse glioma in the United States before year-end. |
globenewswire.com |
2024-12-09 18:01:00 |
Czytaj oryginał (ang.) |
| Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
DURHAM, N.C., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on December 2, 2024, the Compensation Committee of Chimerix's Board of Directors granted inducement awards to three new employees of non-statutory stock options to purchase up to a total of 385,000 shares of Chimerix's common stock. The Compensation Committee of Chimerix's Board of Directors approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing rule 5635(c)(4). |
globenewswire.com |
2024-12-06 18:01:00 |
Czytaj oryginał (ang.) |
| Chimerix, Inc. (CMRX) Q3 2024 Earnings Call Transcript |
Chimerix, Inc. (NASDAQ:CMRX ) Q3 2024 Earnings Call November 7, 2024 8:30 AM ET Company Participants Will O'Connor - Investor Relations Mike Andriole - President and Chief Executive Officer Josh Allen - Chief Scientific Officer Michelle LaSpaluto - Chief Financial Officer Allen Melemed - Chief Medical Officer Tom Riga - Chief Operating and Commercial Officer Conference Call Participants Maury Raycroft - Jefferies Operator Good morning, ladies and gentlemen and welcome to the Chimerix Third Quarter 2024 Earnings Conference Call. I would now like to introduce you to your host for today's call, Will O'Connor from Stern Investor Relations. |
seekingalpha.com |
2024-11-07 23:34:08 |
Czytaj oryginał (ang.) |
| Chimerix (CMRX) Reports Q3 Loss, Lags Revenue Estimates |
Chimerix (CMRX) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.27 per share a year ago. |
zacks.com |
2024-11-07 11:35:22 |
Czytaj oryginał (ang.) |
| Chimerix to Report Third Quarter 2024 Financial Results and Provide an Operational Update on November 7, 2024 |
DURHAM, N.C., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on Thursday, November 7, 2024 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2024, and to provide a business overview. |
globenewswire.com |
2024-11-01 09:00:00 |
Czytaj oryginał (ang.) |
| Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
DURHAM, N.C., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on October 16, 2024, the Compensation Committee of Chimerix's Board of Directors granted an inducement award to a new employee of non-statutory stock options to purchase up to a total of 130,000 shares of Chimerix's common stock. The Compensation Committee of Chimerix's Board of Directors approved the award as an inducement material to the new employee's employment in accordance with Nasdaq Listing rule 5635(c)(4). |
globenewswire.com |
2024-10-18 20:31:00 |
Czytaj oryginał (ang.) |
| Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
DURHAM, N.C., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on August 20, 2024, the Compensation Committee of Chimerix's Board of Directors granted an inducement award to a new employee of non-statutory stock options to purchase up to a total of 150,000 shares of Chimerix's common stock. The Compensation Committee of Chimerix's Board of Directors approved the award as an inducement material to the new employee's employment in accordance with Nasdaq Listing rule 5635(c)(4). |
globenewswire.com |
2024-08-30 20:05:00 |
Czytaj oryginał (ang.) |
| Chimerix (CMRX) Reports Q2 Loss, Misses Revenue Estimates |
Chimerix (CMRX) came out with a quarterly loss of $0.23 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.21 per share a year ago. |
zacks.com |
2024-08-13 13:15:42 |
Czytaj oryginał (ang.) |
| Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
DURHAM, N.C., July 05, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on July 1, 2024, the Compensation Committee of Chimerix's Board of Directors granted inducement awards to two new employees of non-statutory stock options to purchase up to a total of 120,000 shares of Chimerix's common stock. The Compensation Committee of Chimerix's Board of Directors approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing rule 5635(c)(4). |
globenewswire.com |
2024-07-05 20:05:00 |
Czytaj oryginał (ang.) |
| Chimerix to Participate in Fireside Chat at Jefferies Global Healthcare Conference |
DURHAM, N.C., May 30, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Andriole, Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 3:00 p.m. ET. |
globenewswire.com |
2024-05-30 11:00:00 |
Czytaj oryginał (ang.) |
| Chimerix Reports First Quarter 2024 Financial Results and Provides Operational Update |
– Dordaviprone (ONC201) ACTION Study Progressing; Reiterates Expectations for Interim Overall Survival (OS) Data in 2025 and Final OS Data in 2026 – |
globenewswire.com |
2024-05-01 11:00:00 |
Czytaj oryginał (ang.) |
| Chimerix to Report First Quarter 2024 Financial Results and Provide an Operational Update on May 1, 2024 |
DURHAM, N.C., April 24, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on Wednesday, May 1, 2024 at 8:30 a.m. ET to report financial results for the first quarter ended March 31, 2024, and to provide a business overview. |
globenewswire.com |
2024-04-24 11:00:00 |
Czytaj oryginał (ang.) |
| Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
DURHAM, N.C., April 16, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX) today announced that on April 10, 2024, the Compensation Committee of Chimerix's Board of Directors granted inducement awards to four new employees of non-statutory stock options to purchase up to a total of 223,000 shares of Chimerix's common stock. The Compensation Committee of Chimerix's Board of Directors approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing rule 5635(c)(4). |
globenewswire.com |
2024-04-16 20:05:00 |
Czytaj oryginał (ang.) |
| Chimerix: Tackling A Strong Unmet Need With Promising Data |
Chimerix, Inc. is a biotech company focused on developing novel treatments for high-grade glioma and other therapies. Their main clinical asset, doraviprone, has shown promising results in treating H3 K27M-mutated diffuse midline glioma. The company has a strong financial position with over $200 million in assets and a runway of 2+ years, making it an attractive investment for those with a longer-term outlook. |
seekingalpha.com |
2024-03-01 17:31:54 |
Czytaj oryginał (ang.) |
| Chimerix, Inc. (CMRX) Q4 2023 Earnings Call Transcript |
Chimerix, Inc. (CMRX) Q4 2023 Earnings Call Transcript |
seekingalpha.com |
2024-02-29 15:42:02 |
Czytaj oryginał (ang.) |
| Chimerix Reports Fourth Quarter and Year End 2023 Financial Results and Provides Operational Update |
– ONC201 ACTION Study Progressing; Reiterate Interim OS Data Expected in 2025, Final OS Data Expected in 2026 – |
globenewswire.com |
2024-02-29 09:00:00 |
Czytaj oryginał (ang.) |
| Chimerix to Report Fourth Quarter and Year End 2023 Financial Results and Provide an Operational Update on February 29, 2024 |
DURHAM, N.C., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on Thursday, February 29, 2024 at 8:30 a.m. ET to report financial results for the fourth quarter and full-year ended December 31, 2023, and to provide a business overview. |
globenewswire.com |
2024-02-22 09:00:00 |
Czytaj oryginał (ang.) |
| Chimerix Appoints Lisa Decker to Board of Directors |
Seasoned Industry Executive Brings More Than 25 Years of Leadership and Business Development Experience Seasoned Industry Executive Brings More Than 25 Years of Leadership and Business Development Experience |
globenewswire.com |
2023-12-29 09:00:00 |
Czytaj oryginał (ang.) |